PARA023
Prometheus Biosciences, Inc.
['ibd']
 demonstrated efficacy and favorable safety as induction therapy for moderately to severely active uc: phase 2 artemis-uc study results. #ecco2023 #ibd potential dual anti-inflammatory &amp; anti-fibrotic agent?? 
Professor of Medicine, Gastroenterologist, specializing in the care of patients with IBD.
National representative of Germany @ https://t.co/Qr0PthTmU8 ex @Y_ECCO_IBD chair